Elusys Therapeutics Finalizes HHS Contract to Deliver Anthim®, its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Media Center PRESS RELEASE 2022 ELUSYS THERAPEUTICS FINALIZES HHS CONTRACT TO DELIVER ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an […]